Table 3.
Reported home reactions.
| Reactions reported | PaperPRO group (n=14) | OITcontrol group (n=16) | P value | ||||
| Home reactions, n | 56 | 97 | .70 | ||||
| Home reactions/home doses, median (Q1-Q3a) | 0 (0-0.06) | 0 (0-0.07) | .76 | ||||
| Patients with home reactions, n (%) | 9 (64) | 10 (63) | .12 | ||||
| Home reactions/patient, median (Q1-Q3) | 3 (0-5) | 2.5 (0-11.5) | .70 | ||||
| Mild reactions, reactions (affected patients), n | 38 (6) | 73 (8) | .53 | ||||
|
|
Mild OASb | 12 (3) | 37 (7) | .17 | |||
|
|
Relevant OAS (lip edema/perioral urticaria) | 11 (3) | 6 (4) | .95 | |||
|
|
Facial urticaria/angioedema | 7 (3) | 3 (3) | .72 | |||
|
|
Mild gastrointestinal symptoms | 8 (3) | 27 (5) | .47 | |||
| Moderate reactions, reactions (affected patients), n | 13 (6) | 2 (2) | .047 | ||||
|
|
Acute generalized urticaria | 3 (3) | 1 (1) | .23 | |||
|
|
Rhinoconjunctivitis | 10 (4) | 1 (1) | .09 | |||
| Severe reactions, reactions (affected patients), n | 5 (3) | 22 (6) | .21 | ||||
|
|
Severe gastrointestinal symptoms | 1 (1) | 8 (3) | .32 | |||
|
|
Oropharyngeal discomfort | 3 (2) | 9 (4) | .42 | |||
|
|
Bronchospasm | 1 (1) | 0 (0) | .28 | |||
|
|
Anaphylaxis | 0 (0) | 5 (3) | .09 | |||
|
|
Anaphylactic shock | 0 (0) | 0 (0) | >.99 | |||
aQ1-Q3: first quartile-third quartile.
bOAS: oral allergy syndrome.